The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19
Open accessAbstract
This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patients at a single hospital center, all of whom met criteria for severe COVID-19 as well as moderate-to-severe acute respiratory distress syndrome. Patients received a single 15 mL intravenous dose of ExoFlo and were evaluated for both safety and efficacy from days 1 to 14 post-treatment. All safety endpoints were met with no adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Overall, after one treatment, patients' clinical status and oxygenation improved with an average pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) increase of 192% (P < 0.001). Laboratory values revealed significant improvements in absolute neutrophil count [mean reduction 32% (P value <0.001)] and lymphopenia with average CD3+, CD4+, and CD8+ lymphocyte counts increasing by 46% (P < 0.05), 45% (P < 0.05), and 46% (P < 0.001), respectively. Likewise, acute phase reactants declined, with mean C-reactive protein, ferritin, and D-dimer reduction of 77% (P < 0.001), 43% (P < 0.001), and 42% (P < 0.05), respectively. In conclusion, owing to its safety profile, capacity to restore oxygenation, downregulate cytokine storm, and reconstitute immunity, ExoFlo is a promising therapeutic candidate for severe COVID-19. Future randomized controlled trials (RCTs) are needed to determine ExoFlo therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome
Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., & Chiumello, D. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0817le · Cited by 1,396
Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., Shan, G., Meng, F., Du, D., Wang, S., et al. (2020) · Aging and disease · doi:10.14336/ad.2020.0228 · Cited by 1,147
Morrison, T. J., Jackson, M. V., Cunningham, E. K., Kissenpfennig, A., McAuley, D. F., O’Kane, C. M., & Krasnodembskaya, A. D. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0170oc · Cited by 796
Exosomes Derived from Mesenchymal Stem Cells
Yu, B., Zhang, X., & Li, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034142 · Cited by 783
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., Cosgrove, K., Vojnik, R., Calfee, C. S., Lee, J.-W., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70291-7 · Cited by 759
Zhu, Y.-G., Feng, X.-M., Abbott, J., Fang, X.-H., Hao, Q., Monsel, A., Qu, J.-M., Matthay, M. A., & Lee, J. W. (2014) · Stem Cells · doi:10.1002/stem.1504 · Cited by 688
Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application
Wang, M., Yuan, Q., & Xie, L. (2018) · Stem Cells International · doi:10.1155/2018/3057624 · Cited by 505
Extracellular Vesicles: Potential Roles in Regenerative Medicine
De Jong, O. G., Van Balkom, B. W. M., Schiffelers, R. M., Bouten, C. V. C., & Verhaar, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00608 · Cited by 351
Liang, B., Chen, J., Li, T., Wu, H., Yang, W., Li, Y., Li, J., Yu, C., Nie, F., Ma, Z., et al. (2020) · Medicine · doi:10.1097/md.0000000000021429 · Cited by 327
Mesenchymal stem cell–derived extracellular vesicles attenuate kidney inflammation
Eirin, A., Zhu, X.-Y., Puranik, A. S., Tang, H., McGurren, K. A., van Wijnen, A. J., Lerman, A., & Lerman, L. O. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.023 · Cited by 320
Management and Treatment of COVID-19: The Chinese Experience
Peng, F., Tu, L., Yang, Y., Hu, P., Wang, R., Hu, Q., Cao, F., Jiang, T., Sun, J., Xu, G., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.04.010 · Cited by 216
Tang, X.-D., Shi, L., Monsel, A., Li, X.-Y., Zhu, H.-L., Zhu, Y.-G., & Qu, J.-M. (2017) · Stem Cells · doi:10.1002/stem.2619 · Cited by 200
Shao, M., Xu, Q., Wu, Z., Chen, Y., Shu, Y., Cao, X., Chen, M., Zhang, B., Zhou, Y., Yao, R., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-1550-0 · Cited by 200
Katsha, A. M., Ohkouchi, S., Xin, H., Kanehira, M., Sun, R., Nukiwa, T., & Saijo, Y. (2011) · Molecular Therapy · doi:10.1038/mt.2010.192 · Cited by 190
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
Alzghari, S. K., & Acuña, V. S. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104380 · Cited by 163
Anderson, M. R., Kashanchi, F., & Jacobson, S. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0450-6 · Cited by 162
Exosomes in Mesenchymal Stem Cells, a New Therapeutic Strategy for Cardiovascular Diseases?
Huang, L., Ma, W., Ma, Y., Feng, D., Chen, H., & Cai, B. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10725 · Cited by 152
Mesenchymal stem cells and management of COVID-19 pneumonia
Metcalfe, S. M. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100019 · Cited by 150
Exosomes and Exosomal miRNA in Respiratory Diseases
Alipoor, S. D., Mortaz, E., Garssen, J., Movassaghi, M., Mirsaeidi, M. S., & Adcock, I. M. (2016) · Mediators of Inflammation · doi:10.1155/2016/5628404 · Cited by 140
Therapeutic use of mesenchymal stem cell–derived extracellular vesicles in acute lung injury
Lee, J. H., Park, J.-H., & Lee, J. W. (2018) · Transfusion · doi:10.1111/trf.14838 · Cited by 85
Isolation and characterization of microparticles in sputum from cystic fibrosis patients
Porro, C., Lepore, S., Trotta, T., Castellani, S., Ratclif, L., Battaglino, A., Gioia, S. D., Martínez, M. C., Conese, M., & Maffione, A. B. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-94 · Cited by 61
Cited by
The roles of extracellular vesicles in the immune system
Buzas, E. I. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00763-8 · Cited by 1,220
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
Mesenchymal stromal/stem cell (MSC)-Derived exosomes in clinical trials
Lotfy, A., AboQuella, N. M., & Wang, H. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03287-7 · Cited by 482
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 401
Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23618 · Cited by 387
Metadata
- Authors
- Sengupta, V., Sengupta, S., Lazo, A., Woods, P., Nolan, A., & Bremer, N.
- Venue
- Stem Cells and Development
- Publisher
- SAGE Publications
- Published
- 2020-06-15
- Volume
- 29
- Issue
- 12
- Pages
- 747-754
- ISSN
- 1525-8165 (ISSN-L)
- 1547-3287
- 1557-8534
- OpenAlex
- W3023922995
- Cited by
- 748
- References
- 30
- FWCI
- 35.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.